PE20161170A1 - Composiciones farmaceuticas que comprenden azd9291 - Google Patents
Composiciones farmaceuticas que comprenden azd9291Info
- Publication number
- PE20161170A1 PE20161170A1 PE2016000943A PE2016000943A PE20161170A1 PE 20161170 A1 PE20161170 A1 PE 20161170A1 PE 2016000943 A PE2016000943 A PE 2016000943A PE 2016000943 A PE2016000943 A PE 2016000943A PE 20161170 A1 PE20161170 A1 PE 20161170A1
- Authority
- PE
- Peru
- Prior art keywords
- parts
- azd9291
- pharmaceutical
- pharmaceutical compositions
- compositions including
- Prior art date
Links
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003278 osimertinib Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- -1 AZD9291 compound Chemical class 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000001744 Sodium fumarate Substances 0.000 abstract 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical class CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 239000008019 pharmaceutical lubricant Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940005573 sodium fumarate Drugs 0.000 abstract 1
- 235000019294 sodium fumarate Nutrition 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161170A1 true PE20161170A1 (es) | 2016-11-24 |
Family
ID=50191689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000943A PE20161170A1 (es) | 2014-01-02 | 2015-01-02 | Composiciones farmaceuticas que comprenden azd9291 |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| CN110013468B (zh) * | 2018-01-09 | 2022-02-18 | 北京福元医药股份有限公司 | 一种azd9291氘代衍生物药物制剂 |
| WO2019138346A1 (en) * | 2018-01-10 | 2019-07-18 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of osimertinib |
| MA51823A (fr) * | 2018-02-12 | 2021-05-19 | Astrazeneca Ab | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |
| SI3758708T1 (sl) * | 2018-03-01 | 2025-04-30 | Astrazeneca Ab | Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid |
| KR102511672B1 (ko) * | 2018-03-23 | 2023-03-17 | 우시 상량 바이오테크놀로지 씨오., 엘티디. | 의약 조성물, 그 제조방법 및 사용 |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| CN113645976A (zh) | 2019-03-29 | 2021-11-12 | 阿斯利康(瑞典)有限公司 | 用于治疗非小细胞肺癌的奧希替尼 |
| WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CA3166980A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| TW202304457A (zh) * | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
| CN119278041A (zh) | 2022-03-31 | 2025-01-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂 |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| AU2023262556A1 (en) | 2022-04-28 | 2024-12-05 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| MA71241A (fr) | 2022-06-27 | 2025-04-30 | Astrazeneca Ab | Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer |
| JP2025522965A (ja) | 2022-07-08 | 2025-07-17 | アストラゼネカ・アクチエボラーグ | 癌の治療のためのｈｇｆ受容体阻害剤と組み合わせた上皮成長因子受容体チロシンキナーゼ阻害剤 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025092926A1 (zh) * | 2023-10-31 | 2025-05-08 | 浙江同源康医药股份有限公司 | 一种嘧啶类衍生物的药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| WO2001076565A1 (fr) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions et preparations se desintegrant dans la cavite buccale |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| MY135609A (en) | 2002-02-26 | 2008-05-30 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| WO2006037763A1 (en) | 2004-10-05 | 2006-04-13 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| KR20080101888A (ko) * | 2006-02-09 | 2008-11-21 | 다이이찌 산쿄 가부시키가이샤 | 항암 의약 조성물 |
| JP5576922B2 (ja) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | 腸溶性固体分散体を含んでなる固形製剤 |
| AU2008274941A1 (en) * | 2007-07-12 | 2009-01-15 | Tragara Pharmaceuticals, Inc. | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
| EP2696857A1 (en) | 2011-04-11 | 2014-02-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical composition comprising bosentan |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| EP2736895B1 (en) * | 2011-07-27 | 2016-01-06 | Astrazeneca AB | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| EP3181128B1 (en) * | 2012-01-13 | 2023-03-08 | XSpray Pharma AB (publ) | Nilotinib pharmaceuticalcomposition |
| WO2013160916A1 (en) | 2012-04-25 | 2013-10-31 | Hetero Research Foundation | Sunitinib malate solid dispersion |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
-
2014
- 2014-01-02 GB GBGB1400034.3A patent/GB201400034D0/en not_active Ceased
- 2014-12-29 UY UY0001035933A patent/UY35933A/es not_active Application Discontinuation
- 2014-12-29 AR ARP140104947A patent/AR098989A1/es not_active Application Discontinuation
- 2014-12-31 TW TW103146652A patent/TWI702953B/zh active
-
2015
- 2015-01-02 PL PL15700082T patent/PL3089741T3/pl unknown
- 2015-01-02 RS RS20210698A patent/RS61927B1/sr unknown
- 2015-01-02 WO PCT/GB2015/050001 patent/WO2015101791A1/en not_active Ceased
- 2015-01-02 CA CA2933403A patent/CA2933403C/en active Active
- 2015-01-02 CN CN201580003266.4A patent/CN105848647B/zh active Active
- 2015-01-02 EP EP15700082.9A patent/EP3089741B1/en active Active
- 2015-01-02 LT LTEP15700082.9T patent/LT3089741T/lt unknown
- 2015-01-02 AU AU2015204218A patent/AU2015204218B2/en active Active
- 2015-01-02 EA EA201691242A patent/EA034243B9/ru not_active IP Right Cessation
- 2015-01-02 CR CR20160310A patent/CR20160310A/es unknown
- 2015-01-02 SM SM20210330T patent/SMT202100330T1/it unknown
- 2015-01-02 HR HRP20210749TT patent/HRP20210749T1/hr unknown
- 2015-01-02 SI SI201531610T patent/SI3089741T1/sl unknown
- 2015-01-02 DK DK15700082.9T patent/DK3089741T3/da active
- 2015-01-02 PH PH1/2016/501310A patent/PH12016501310B1/en unknown
- 2015-01-02 PE PE2016000943A patent/PE20161170A1/es unknown
- 2015-01-02 KR KR1020167020731A patent/KR102336378B1/ko active Active
- 2015-01-02 MY MYPI2016702433A patent/MY183536A/en unknown
- 2015-01-02 PT PT157000829T patent/PT3089741T/pt unknown
- 2015-01-02 ES ES15700082T patent/ES2873226T3/es active Active
- 2015-01-02 SG SG11201605339QA patent/SG11201605339QA/en unknown
- 2015-01-02 US US15/109,170 patent/US10183020B2/en active Active
- 2015-01-02 NZ NZ721298A patent/NZ721298A/en unknown
- 2015-01-02 HU HUE15700082A patent/HUE054344T2/hu unknown
- 2015-01-02 CN CN202210324141.3A patent/CN114712362A/zh active Pending
- 2015-01-02 MX MX2016008744A patent/MX367358B/es active IP Right Grant
- 2015-01-02 JP JP2016544368A patent/JP6588915B2/ja active Active
-
2016
- 2016-06-13 IL IL246186A patent/IL246186B/en active IP Right Grant
- 2016-06-22 CL CL2016001609A patent/CL2016001609A1/es unknown
- 2016-06-22 DO DO2016000156A patent/DOP2016000156A/es unknown
- 2016-06-29 GT GT201600142A patent/GT201600142A/es unknown
- 2016-07-01 NI NI201600098A patent/NI201600098A/es unknown
- 2016-08-01 ZA ZA2016/05300A patent/ZA201605300B/en unknown
-
2018
- 2018-11-20 US US16/196,185 patent/US20190111057A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/984,276 patent/US20200360378A1/en not_active Abandoned
-
2021
- 2021-06-08 CY CY20211100499T patent/CY1124848T1/el unknown
- 2021-09-17 US US17/478,117 patent/US20240189310A1/en not_active Abandoned
-
2022
- 2022-04-26 US US17/729,162 patent/US20220395502A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,609 patent/US20250017930A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161170A1 (es) | Composiciones farmaceuticas que comprenden azd9291 | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| MX2018010805A (es) | Agentes antivirales contra la hepatitis b. | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| MX2017008386A (es) | Administración específica del sitio de un inhibidor de btk. | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| MX384800B (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| MX2014015185A (es) | Derivados deuterados de ruxolitinib. | |
| MX2014005342A (es) | Inhibidores del virus de la hepatitis c. | |
| MX376329B (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| UY34027A (es) | Inhibidores sustituidos de acetil-coa carboxilasa. | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| EA201790655A1 (ru) | Новые активаторы растворимой гуанилатциклазы и их применение | |
| MY181641A (en) | Amino pyran ring derivative and composition and use thereof | |
| UY36257A (es) | “compuestos de imidazopiridazina”. | |
| EA201790046A1 (ru) | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| CR20180091A (es) | 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний |